Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Pasritamig (Bispecific Antibody) in Advanced prostate cancer. The expected timing is based on the latest available company guidance and may change.
08/06/26:- Ph1b data expected H2 2026; Ph3 mCRPC completion moved to Dec 2027.
Verification
Confirm timing and program details against the company announcement or filing.